First Time Loading...

BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 92.24 USD 2.55% Market Closed
Updated: May 3, 2024
Section:
 

Wall Street
Price Targets

BNTX Price Targets Summary
BioNTech SE

Wall Street analysts forecast BNTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNTX is 120.95 USD with a low forecast of 90.9 USD and a high forecast of 179.55 USD.

BNTX Lowest Forecast
Wall Street Target
90.9 USD
1% Downside
BNTX Average Forecast
Wall Street Target
120.95 USD
31% Upside
BNTX Highest Forecast
Wall Street Target
179.55 USD
95% Upside
Lowest
Price Target
90.9 USD
1% Downside
Average
Price Target
120.95 USD
31% Upside
Highest
Price Target
179.55 USD
95% Upside

BNTX Last Price Targets
BioNTech SE

The latest public price target was made on Mar 22, 2024 by Yifeng Liu from HSBC , who expects BNTX stock to drop by 2% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Yifeng Liu
HSBC
90 USD
Downside 2%
1 month ago
Mar 22, 2024
BioNTech (BNTX) PT Lowered to $90 at HSBC, 'near-term COVID-19 revenue still remains a risk overhang'
StreetInsider
Chris Shibutani
Goldman Sachs
91 USD
Downside 1%
1 month ago
Mar 21, 2024
BioNTech (BNTX) PT Lowered to $91 at Goldman Sachs
StreetInsider
William Maughan
Canaccord Genuity
171 USD
Upside 85%
1 month ago
Mar 21, 2024
Canaccord Genuity Reviews BioNTech (BNTX) Post Earnings
StreetInsider
Etzer Darout
BMO Capital
123 USD
Upside 33%
1 month ago
Mar 21, 2024
BioNTech (BNTX) PT Lowered to $123 at BMO Capital
StreetInsider
Unknown Analyst
Goldman Sachs
156 USD
Upside 69%
1 year ago
Jan 31, 2023
Goldman Sachs Maintains Neutral on BioNTech, Lowers Price Target to $156
Benzinga
Yifeng Liu
HSBC
Price Target 90 USD
Upside/Downside 2%
View Source
Chris Shibutani
Goldman Sachs
Price Target 91 USD
Upside/Downside 1%
View Source
William Maughan
Canaccord Genuity
Price Target 171 USD
Upside/Downside 85%
View Source
Etzer Darout
BMO Capital
Price Target 123 USD
Upside/Downside 33%
View Source
Unknown Analyst
Goldman Sachs
Price Target 156 USD
Upside/Downside 69%
View Source
BioNTech SE Competitors:
Price Targets
302440
SK Bioscience Co Ltd
4% Downside
INCY
Incyte Corp
43% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
71% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
56% Upside
302440
SK Bioscience Co Ltd
4% Downside
INCY
Incyte Corp
43% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
71% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
56% Upside
GTH
Genetron Holdings Ltd
67% Downside
J
7774
Japan Tissue Engineering Co Ltd
92% Upside
H
042520
Hans Biomed Corp
174% Upside
CTMX
CytomX Therapeutics Inc
34% Downside

Revenue
Forecast

Revenue Estimate
BioNTech SE

For the last 5 years the compound annual growth rate for BioNTech SE's revenue is 97%. The projected CAGR for the next 3 years is -8%.

97%
Past Growth
-8%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
BioNTech SE

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
BioNTech SE

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

See Also

Summary
BNTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
BNTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BNTX stock valuation using valuation multiples.
Wall Street Estimates
BNTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BNTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BNTX's stock price target?
Price Target
120.95 USD

According to Wall Street analysts, the average 1-year price target for BNTX is 120.95 USD with a low forecast of 90.9 USD and a high forecast of 179.55 USD.

What is BioNTech SE's Revenue forecast?
Projected CAGR
-8%

For the last 5 years the compound annual growth rate for BioNTech SE's revenue is 97%. The projected CAGR for the next 3 years is -8%.

ALPHA SPREAD
Join more than 133,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.